EGR1 and myeloid sarcoma: In summary, we provide the first evidence to identify the involvement of SCL22A17/EGR1 in LCN2-mediated insufficient OPC remyelination in both typical/chronic WM disorders (MS) and atypical/acute WM disorders (SAH), although these diseases have distinct etiologies.